Literature DB >> 19910218

Dynamic contrast enhancement of experimental glioma an intra-individual comparative study to assess the optimal time delay.

Tobias Engelhorn1, Marc A Schwarz, Ilker Y Eyupoglu, Stephan P Kloska, Tobias Struffert, Arnd Doerfler.   

Abstract

RATIONALE AND
OBJECTIVES: The aim of this study was to compare tumor signal and contrast media uptake characteristics on contrast-enhanced T1-weighted sequences at 3 Tesla over 30 minutes after double-dose administration of different contrast agents in an animal model of brain glioma.
MATERIALS AND METHODS: Nine rats underwent magnetic resonance imaging (MRI) after stereotactic F98 glioma cell implantation before and repetitively for 30 minutes after injection of gadobutrol, gadopentetate, and gadobenate, respectively. Signal-to-noise ratio (SNR) and tumor contrast-to-noise ratio (CNR) were evaluated and MRI-derived tumor volumes were compared to histology.
RESULTS: Postcontrast tumor SNR and CNR peaked at 4 minutes after contrast application. While contrast-enhancement within the tumor was fading, tumor volume increased by continuous contrast-uptake of peripheral parts between 4 minutes (137 + or - 29 mm(3), 126 + or - 16 mm(3), 141 + or - 24 mm(3)) and 20 minutes (182 + or - 35 mm(3), 164 + or - 32 mm(3), 191 + or - 25 mm(3)), respectively. At 8 and 12 minutes, 84% and 91% of the tumor volume were definable, respectively.
CONCLUSION: Optimal correlation between MRI-derived tumor volume and histology is achieved by imaging up to 20 minutes after contrast application. At 4 minutes (this delay is mostly used in clinical routine), only 75% of the enhancing tumor volume is assessable. A delay of 8 minutes already reveals 84% of the tumor and seems to be a practical clinical compromise. Copyright 2010 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19910218     DOI: 10.1016/j.acra.2009.08.014

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  5 in total

Review 1.  MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice.

Authors:  M Essig; N Anzalone; S E Combs; À Dörfler; S-K Lee; P Picozzi; A Rovira; M Weller; M Law
Journal:  AJNR Am J Neuroradiol       Date:  2011-10-20       Impact factor: 3.825

2.  MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.

Authors:  Marc Saake; Soenke Langner; Carsten Schwenke; Marina Weibart; Olav Jansen; Norbert Hosten; Arnd Doerfler
Journal:  Eur Radiol       Date:  2015-06-30       Impact factor: 5.315

3.  Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read.

Authors:  M Koenig; G Schulte-Altedorneburg; M Piontek; A Hentsch; P Spangenberg; C Schwenke; A Harders; L Heuser
Journal:  Eur Radiol       Date:  2013-07-04       Impact factor: 5.315

4.  Time optimization of gadobutrol-enhanced brain MRI for metastases and primary tumors using a dynamic contrast-enhanced imaging.

Authors:  Jeemin Seo; Changmok Lim; Kye Young Lee; Young-Cho Koh; Won-Jin Moon
Journal:  BMC Med Imaging       Date:  2022-10-17       Impact factor: 2.795

5.  MRI assessment of experimental gliomas using 17.6 T.

Authors:  Marc A Schwarz; Mirko Pham; Xavier Helluy; Arnd Doerfler; Tobias Engelhorn
Journal:  Neuroradiology       Date:  2013-03-10       Impact factor: 2.804

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.